ATE481644T1 - Prognose des verlaufs einer krebserkrankung - Google Patents

Prognose des verlaufs einer krebserkrankung

Info

Publication number
ATE481644T1
ATE481644T1 AT04733219T AT04733219T ATE481644T1 AT E481644 T1 ATE481644 T1 AT E481644T1 AT 04733219 T AT04733219 T AT 04733219T AT 04733219 T AT04733219 T AT 04733219T AT E481644 T1 ATE481644 T1 AT E481644T1
Authority
AT
Austria
Prior art keywords
concentration
amount
protein
correlating
cancer
Prior art date
Application number
AT04733219T
Other languages
English (en)
Inventor
Sven Skog
Staffan Eriksson
Bernhard Tribukait
Qimin He
Original Assignee
Arocell Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arocell Ab filed Critical Arocell Ab
Application granted granted Critical
Publication of ATE481644T1 publication Critical patent/ATE481644T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT04733219T 2003-05-16 2004-05-14 Prognose des verlaufs einer krebserkrankung ATE481644T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47124503P 2003-05-16 2003-05-16
PCT/SE2004/000750 WO2004100760A1 (en) 2003-05-16 2004-05-14 Predicting cancer progression

Publications (1)

Publication Number Publication Date
ATE481644T1 true ATE481644T1 (de) 2010-10-15

Family

ID=33452434

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04733219T ATE481644T1 (de) 2003-05-16 2004-05-14 Prognose des verlaufs einer krebserkrankung

Country Status (7)

Country Link
US (4) US20070141650A1 (de)
EP (1) EP1627230B1 (de)
JP (1) JP4668180B2 (de)
AT (1) ATE481644T1 (de)
DE (1) DE602004029156D1 (de)
ES (1) ES2353014T3 (de)
WO (1) WO2004100760A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2353014T3 (es) * 2003-05-16 2011-02-24 Arocell Ab Predicción de la evolución del cáncer.
US8765378B2 (en) * 2005-02-25 2014-07-01 Biovica International Ab Method and kit for determination of thymidine kinase activity and use thereof
US8501419B2 (en) * 2007-05-23 2013-08-06 Arocell Ab Exposed proliferation-related peptides, ligands and methods employing the same
JP6312660B2 (ja) * 2013-05-17 2018-04-18 大鵬薬品工業株式会社 Ｔｋ１タンパク質の発現が亢進した結腸直腸癌患者に対する治療効果予測方法
ES2823351T3 (es) 2013-12-19 2021-05-06 Arocell Ab Anticuerpos anti-TK1 monoclonales
JP7015294B2 (ja) * 2016-08-10 2022-03-04 アラーティクス ヴェテリナリー ダイアグノスティクス エービー 非ヒト哺乳動物ｔｋ１タンパク質レベルの決定
EP3781600A1 (de) * 2018-04-18 2021-02-24 F. Hoffmann-La Roche AG Neuartige anti-thymidinkinase-antikörper
CN110873711B (zh) * 2018-09-04 2022-02-22 华瑞同康生物技术（深圳）有限公司 一种基于全自动化学发光分析仪的血清tk1检测试剂盒
US12578340B2 (en) 2022-06-03 2026-03-17 Alertix Veterinary Diagnostics Ab Determination of canine TK1 protein levels

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4317877A (en) * 1980-06-05 1982-03-02 Sloan Kettering Institute Process for detecting the presence of malignant and pre-malignant cells in humans
ATE239784T1 (de) * 1993-08-06 2003-05-15 Univ Brigham Young Monoklonale antikörper gegen isozyme der thymidinkinase
SE9401380D0 (sv) * 1994-04-22 1994-04-22 Sven Skog Ny celltillväxt-relaterad peptid och användning därav
US6678669B2 (en) * 1996-02-09 2004-01-13 Adeza Biomedical Corporation Method for selecting medical and biochemical diagnostic tests using neural network-related applications
ATE352039T1 (de) 2002-07-27 2007-02-15 Diasorin Ab Verfahren zur bestimmung der aktivität von thymidinkinase-1 und dessen verwendung
ES2353014T3 (es) * 2003-05-16 2011-02-24 Arocell Ab Predicción de la evolución del cáncer.

Also Published As

Publication number Publication date
JP4668180B2 (ja) 2011-04-13
JP2006526156A (ja) 2006-11-16
WO2004100760A8 (en) 2005-02-03
US20070141650A1 (en) 2007-06-21
EP1627230B1 (de) 2010-09-15
US11959919B2 (en) 2024-04-16
US10551385B2 (en) 2020-02-04
US20100311081A1 (en) 2010-12-09
US20200124608A1 (en) 2020-04-23
WO2004100760A1 (en) 2004-11-25
EP1627230A1 (de) 2006-02-22
US20170067900A1 (en) 2017-03-09
ES2353014T3 (es) 2011-02-24
DE602004029156D1 (de) 2010-10-28

Similar Documents

Publication Publication Date Title
RU2408735C2 (ru) Способ предсказания ответа на лечение
DE60233744D1 (de) Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper-komplexe mit elisa-tests
BRPI0415230A (pt) anticorpo biespecìfico de substituição de proteìnas funcionais
DE60335022D1 (de) Internalisierende Antikörper spezifisch für das RAAG10 Zelloberflächenziel
NO20076656L (no) Forbedrede immunoassay metoder
EA030259B8 (ru) Человеческие нейтрализующие антитела к фактору роста нервов (ngf) в качестве селективных ингибиторов метаболического пути ngf
DE59903915D1 (de) Verfahren zur frühen diagnose von carcinomen
WO2004058044A3 (en) Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
NO20050775L (no) Fremgangsmater for identifisering av tumorer som responderer pa behandling med anti-ErbB2-antistoffer
ATE348843T1 (de) Nachweis von tsh-rezeptor-autoantikörpern mit affinitätsgereinigten antikörpern
BRPI0210579B8 (pt) anticorpo e composição farmacêutica
UA90082C2 (ru) Выделенное моноклональное антитело человека, которое специфически связывается с cd25 человека и ингибирует связывание il-2 с cd25
WO2005010213A3 (en) Markers for detection of gastric cancer
ATE372784T1 (de) Rekombinante proteine, die epitope des humanen papillomavirus inseriert in einem adenylatecyclase protein oder in dessen fragmenten tragen, und deren terapeutischen verwendung.
MX2019007500A (es) Antagonistas de il-6 para aumentar la albumina y/o disminuir la crp.
BRPI0812875A2 (pt) " método pra identificar se ou não um indivíduo está sob risco de desenvolvimento de sépsis severa, anticorpo específico para proteína ligante de heparina, método pra reduzir o risco de um indivíduo desenvolver sépsis severa, e, kit de teste ".
DE60025347D1 (de) Methoden zur vohersage eines schwangerschaftsergebnisses bei einer testperson mit hilfe eines hcg-tests
DE602004029156D1 (de) Prognose des verlaufs einer krebserkrankung
WO2003092601A3 (en) A method for detecting lysosomal storage diseases
ATE258310T1 (de) Testverfahren für collagenpeptid
DE602006021777D1 (de) Diagnoseverfahren für präeklampsie
SE8701905D0 (sv) A method and a kit for the diagnosis of iga nephropathy
EP4283304A2 (de) Verfahren zum nachweis von anti-leptin-neutralisierenden antikörpern
WO2005019831B1 (en) Methods for reducing complexity of a sample using small epitope antibodies
WO2010028313A3 (en) Phosphoprotein analysis of carcinomas for assessment of drug sensitivity

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties